RT Journal Article
SR Electronic
T1 COVID-19 Associated Mucormycosis: Scoping Review Protocol
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.30.21258068
DO 10.1101/2021.05.30.21258068
A1 Salman Hussain
A1 Harveen Baxi
A1 Abanoub Riad
A1 Jitka Klugarová
A1 Radim Líčeník
A1 Miloslav Klugar
YR 2021
UL http://medrxiv.org/content/early/2021/06/01/2021.05.30.21258068.abstract
AB Background and Objective Mucormycosis, a serious and rare fungal infection, has occurred concurrently in COVID-19 patients globally. Mucormycosis is associated with a high risk of all-cause mortality, with mortality depending on body site infected, fungus type, and the patient’s overall condition. This deadly fungal infection is quite difficult and expensive to treat. Therefore, this scoping review aims to map all the empirical evidence on the COVID-19 associated mucormycosis with a special focus on clinical presentation, treatment, and patient outcomes.Methods The proposed scoping review will be developed by adhering to the JBI methodology for scoping reviews and will be reported as per the Preferred Reporting Items for Systematic Reviews and Meta-analyses for Scoping Reviews (PRISMA-ScR). A detailed search strategy has already been utilized to locate both published and unpublished studies. Literature search was carried out in three phases. PubMed, Scopus, Cochrane, Google scholar was searched. We will include all those studies which are presenting mucormycosis cases in COVID-19 positive patients. Data will be extracted in a pre-designed data extraction sheet and risk of bias will be assessed using JBI critical appraisal tool. The primary outcome will be to summarize the clinical presentation, treatment, and patient outcomes in COVID-19 associated mucormycosis. Data will be presented in tabular form.OSF registration number osf.io/438smCompeting Interest StatementThe authors have declared no competing interest.Funding StatementSalman Hussain is supported from Operational Programme Research, Development and Education Project, Postdoc2MUNI (No. CZ.02.2.69/0.0/0.0/18_053/0016952); Miloslav Klugar, Abanoub Riad, Radim Ličenik and Jitka Klugarova are supported by the INTER-EXCELLENCE grant number LTC20031 Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic. The work of Abanoub Riad is also supported by Masaryk University grants MUNI/IGA/1543/2020 and MUNI/A/1608/2020.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB approval is exempted because this is a scoping reviewAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request.